| Literature DB >> 27832777 |
Zhen Li1, Bohong Chen1, Ping Wang1, Xin Li1, Gaotai Cai1, Wei Wei1, Wenqi Dong2.
Abstract
BACKGROUND: 9s-hydroxy-octadecadienoic acid (9S-HOD), one of the natural products of linoleic acid oxygenation by 15-lipoxygenase (15-LOX), has been found to have anti-tumor properties in vitro and in vivo. The present study therefore investigated whether 9S-HOD affects acute leukemia HL-60 cells.Entities:
Keywords: 9s-hydroxy-octadecadienoic acid; Acute leukemia cells; Bioinformatics analysis; Proteomics
Mesh:
Substances:
Year: 2016 PMID: 27832777 PMCID: PMC5105288 DOI: 10.1186/s12944-016-0359-4
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Fig. 1The cell viability of HL-60 cell treated with/without 9S-HOD in different culture media. a Effects of 9S-HOD for 24 h in + FBS, −FBS, CD and AIM-V media. b Effects of 9S-HOD for 48 h in + FBS, −FBS, CD and AIM-V media. c The cell viability of HL-60 cell for 24 ~ 72 h in + FBS, −FBS and CD media. d Effects of 9S-HOD or 10 t,12c-CLA for 48 h in CD medium. B: blank; V: vehicle; HOD: 9S-HOD; +FBS: RPMI medium containing 5 % FBS; −FBS: RPMI medium without FBS (serum free); CD: CD hybridoma medium (serum free); AIM-V: AIM-V medium (serum free). **P < 0.01, ***P < 0.001
Fig. 29S-HOD induces HL-60 cell apoptosis. Morphological analysis of HL-60 cell after a vehicle or b 20 μM 9S-HOD treatment for 48 h, and c apoptosis examined using Annexin V/PI staining and flow cytometry. *P < 0.05, ***P < 0.001
Fig. 3Two-DE profiles of a vehicle or b 20 μM 9S-HOD treatment of HL-60 for 48 h. Total protein exacts were separated on pH 3–10, 17 cm IPG strips and stained with silver. MS-based identification of these spots is summarized in Table 1
The identification of protein spots on 2-DE
| Spot | Accession | Protein name | Gene | M.W. | pI | Score |
|---|---|---|---|---|---|---|
| mRNA metabolic process | ||||||
| 13 | Q69YN4 | Protein virilizer homolog↓ | KIAA1429 | 202584.08 | 4.44 | 66.6 |
| 9 | Q13185 | Chromobox protein homolog 3↓ | CBX3 | 20969.41 | 4.96 | 84.6 |
| 22 | P61978 | Heterogeneous nuclear ribonucleoprotein K↑ | HNRNPK | 48760.25 | 5.17 | 54.5 |
| Protein binding | ||||||
| 32 | P60709 | Actin, cytoplasmic 1 ↑ | ACTB | 42051.86 | 5.15 | 122 |
| 23 | P05388 | 60S acidic ribosomal protein P0↑ | RPLP0 | 34388.88 | 5.77 | 170 |
| 29 | P11171 | Protein 4.1↑ | EPB41 | 81755.32 | 5.54 | 61 |
| 6 | Q6PK50 | HSP90AB1 protein↓ | HSP90AB1 | 40270.42 | 4.61 | 78.6 |
| DNA replication | ||||||
| 1 | Q01105 | Protein SET↓ | SET | 30974.22 | 3.86 | 98 |
| 2 | Q01105 | Protein SET↓ | SET | 31310.48 | 3.83 | 202 |
| 5 | P12004 | Proliferating cell nuclear antigen↓ | PCNA | 29092.42 | 4.31 | 94.1 |
| Cytoskeleton | ||||||
| 21 | P63261 | Actin, cytoplasmic 2 ↑ | ACTG1 | 42107.92 | 5.16 | 321 |
| 17 | I3L1U9 | Actin, cytoplasmic 2, N-terminally processed↑ | ACTG1 | 23886.98 | 5.11 | 129 |
| Apoptosis process | ||||||
| 26 | P51878 | Caspase-5↑ | CASP5 | 33966.33 | 8.55 | 60.4 |
| Negative regulation of myeloid cell differentiation | ||||||
| 4 | E9PKG1 | Protein arginine N-methyltransferase 1↓ | PRMT1 | 38198.03 | 6.06 | 106 |
| Unknown | ||||||
| 8 | P35527 | Keratin, type I cytoskeletal 9↓ | KRT9 | 62254.9 | 4.89 | 67.1 |
| 31 | Q15195 | Plasminogen-like protein A↑ | PLGLA | 11135.6 | 6.5 | 63.6 |
| 28 | Q8IUZ0 | Isoform 3 of Leucine-rich repeat-containing protein↑ | LRRC49 | 74491.59 | 7.15 | 60 |
| 27 | B4DVQ0 | cDNA FLJ58286, highly similar to Actin, cytoplasmic 2↑ | 37666.76 | 5.45 | 147 | |
| 20 | B4E335 | cDNA FLJ52842, highly similar to Actin, cytoplasmic 1↑ | 39542.66 | 5.28 | 207 | |
| 19 | B4DW52 | cDNA FLJ55253, highly similar to Actin, cytoplasmic 1↑ | 38950.3 | 5 | 148 | |
Fig. 4Distribution of GO annotations of biological functions for identified proteins. a Multi-level pie chart of combined graph of GO biological functions annotations by Genecodis2; b The network of proteins was generated by STRING